Back to Journals » Infection and Drug Resistance » Volume 13

Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators

Authors Kordzadeh-Kermani E, Khalili H, Karimzadeh I, Salehi M

Received 1 October 2019

Accepted for publication 29 January 2020

Published 18 February 2020 Volume 2020:13 Pages 513—532


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Eric Nulens

Elaheh Kordzadeh-Kermani,1 Hossein Khalili,1 Iman Karimzadeh,2 Mohammadreza Salehi3

1Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; 2Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 3Department of Infectious Diseases, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Correspondence: Hossein Khalili
Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, P.o. Box 14155/6451, Tehran, Iran
Tel/Fax +98 216 695 4709

Abstract: The introduction of biologic and targeted immunomodulators is a significant breakthrough in the therapeutic area of various fields of medicine. The occurrence of serious infections, a complication of secondary immunosuppression associated with these agents, leads to increased morbidity and mortality. Implementing preventive strategies could minimize infection-related complications and improve therapeutic outcomes. The purpose of this review is to focus on current evident approaches regarding screening, monitoring, preventing (immunization and chemoprophylaxis), and management of infections in patients who are candidates for about 70 biologic and targeted immunomodulators. Recommendations are based on relevant guidelines, especially the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document series published in 2018.

Keywords: biologic immunomodulators, targeted immunomodulators, immunization, chemoprophylaxis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]